Palisade Bio to Participate in the Jefferies Global Healthcare Conference

Palisade Bio (Nasdaq:PALI), a clinical-stage biopharma developing once-daily oral PDE4 inhibitor prodrugs for targeted delivery to the terminal ileum and colon, will present at the Jefferies Global Healthcare Conference in New York.

Rhea-AI Summary

Palisade Bio (Nasdaq:PALI), a clinical-stage biopharma developing once-daily oral PDE4 inhibitor prodrugs for targeted delivery to the terminal ileum and colon, will present at the Jefferies Global Healthcare Conference in New York.

The management presentation is scheduled for Thursday, June 4, 2026, at 3:45 PM ET, with a live webcast and limited-time replay available on the company's investor relations Events page. Management will also hold one-on-one meetings with qualified, registered investors.

Argus May 27 session

+4.02% close to close Open Argus

Details

News Market Reaction – PALI

On May 27, the day this news came out, PALI closed 4.02% above the previous close.

Data tracked by StockTitan Argus for the May 27 session.

Market Context

This announcement highlights Palisade Bio’s participation at a major healthcare conference, offering...

Analysis

This announcement highlights Palisade Bio’s participation at a major healthcare conference, offering management a platform on June 4, 2026 at 3:45 PM ET to engage investors and discuss its clinical programs. Shares traded at 1.99, below the 52-week high 2.855 but above the 200-day MA 1.68. Investors may watch for messaging consistency with recent filings and how the company frames future use of its $300,000,000 shelf and upcoming trial plans.

Key Figures

Conference dates: June 2–4, 2026 Presentation date: June 4, 2026 Presentation time: 3:45 PM ET

Conference dates

June 2–4, 2026

Jefferies Global Healthcare Conference schedule

Presentation date

June 4, 2026

Palisade Bio management presentation

Presentation time

3:45 PM ET

Scheduled Jefferies conference slot

Historical Context

5 past events · Latest: May 12

5 events

1. May 12

   Q1 2026 earnings

   24h Move

   -2.6%

   Quarterly results and PALI-2108 clinical progress with strong cash balance.

2. May 05

   Clinical data update

   24h Move

   -7.5%

   Additional Phase 1a/b data showing colon-targeted exposure and IC90 coverage.

3. Apr 16

   Conference poster selection

   24h Move

   -0.4%

   Poster acceptance at DDW 2026 for PALI-2108 Phase 1 findings in UC.

4. Apr 08

   Investor conference presentation

   24h Move

   -2.1%

   Needham healthcare conference presentation and investor one-on-one meetings.

5. Mar 30

   Phase 1b topline data

   24h Move

   -1.7%

   Positive Phase 1b results in fibrostenotic Crohn’s disease for PALI-2108.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pde4 inhibitor prodrugs, terminal ileum

2 terms

pde4 inhibitor prodrugs medical

"oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum"

PDE4 inhibitor prodrugs are inactive chemical versions of drugs designed to become active inhibitors of the PDE4 enzyme once processed in the body; PDE4 controls cellular signals linked to inflammation and other conditions. Think of a prodrug as a sealed package that opens inside the body to release the real medicine. Investors care because prodrugs can improve how well a drug works, reduce side effects, extend patent life or simplify dosing, all of which affect clinical success, regulatory approval and commercial value.

terminal ileum medical

"designed for targeted delivery to the terminal ileum and colon"

The terminal ileum is the final segment of the small intestine that connects to the large intestine; think of it as the doorway between two rooms of the digestive tract where nutrients are absorbed and waste moves on. It matters to investors because many gastrointestinal diseases, targeted drugs, diagnostic tests, and surgical procedures focus on this specific site, so outcomes or regulatory news about treatments affecting the terminal ileum can materially influence clinical trial results, approvals, and a company’s financial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Management presentation to take place on Thursday, June 4^th at 3:45 PM ET

Register for the webcast here

Denver, CO, May 27, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will present at the Jefferies Global Healthcare Conference, being held June 2-4, 2026, in New York, New York.

The Company’s presentation is scheduled for Thursday, June 4, 2026, at 3:45 PM ET. A live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website at palisadebio.com. A replay will be available following the live event and will be archived for a limited time.

In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered for the conference.

About Palisade Bio

Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company advancing a next-generation oral PDE4 inhibitor prodrug designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into improved, differentiated oral therapies for patients living with chronic inflammatory and fibrotic diseases.

The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. PALI-2108 has demonstrated positive results in a Phase 1a and two Phase 1b clinical trials, including studies in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD).

Palisade Bio is now advancing towards Phase 2 clinical studies in UC and Crohn’s disease. For more information, please go to www.palisadebio.com.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Palisade Bio (PALI) present at the Jefferies Global Healthcare Conference 2026?

Palisade Bio will present on Thursday, June 4, 2026, at 3:45 PM ET. According to the company, this presentation is part of the Jefferies Global Healthcare Conference held June 2-4, 2026, in New York.

How can investors watch Palisade Bio's Jefferies Global Healthcare Conference 2026 presentation?

Investors can watch a live webcast of Palisade Bio's presentation via the Events page in the Investors section of palisadebio.com. According to the company, a replay will be available and archived for a limited time.

Who will present for Palisade Bio (PALI) at the Jefferies Global Healthcare Conference 2026?

The presenters will be JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer. According to Palisade Bio, they will deliver the company’s conference presentation and meet investors.

Will Palisade Bio management hold investor meetings at the Jefferies Global Healthcare Conference 2026?

Yes, Palisade Bio management will be available for one-on-one meetings with qualified investor community members. According to the company, these meetings are limited to investors who are registered for the conference.

What type of drugs is Palisade Bio (PALI) developing as a clinical-stage company?

Palisade Bio is developing next-generation, once-daily, oral PDE4 inhibitor prodrugs for targeted delivery to the terminal ileum and colon. According to the company, these candidates are part of its clinical-stage biopharmaceutical pipeline.